These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23219462)

  • 1. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
    Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
    Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
    Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
    Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
    Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
    Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.
    Braga Lda C; Alvares da Silva Ramos AP; Traiman P; Silva LM; Lopes da Silva-Filho A
    Gynecol Oncol; 2012 Aug; 126(2):268-73. PubMed ID: 22555108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
    Ahluwalia A; Yan P; Hurteau JA; Bigsby RM; Jung SH; Huang TH; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):261-8. PubMed ID: 11531277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
    Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
    Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
    Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
    Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.
    Guerrero K; Wang Z; Bachvarova M; Gregoire J; Renaud MC; Plante M; Bachvarov D
    Gynecol Oncol; 2012 Jun; 125(3):720-6. PubMed ID: 22446619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.